Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 15 (5) , 383-391
- https://doi.org/10.1097/01.mbc.0000114441.59147.56
Abstract
Urokinase-type plasminogen activator (UPA) has been implicated in a broad spectrum of pathogenic processes involved in the formation and disruption of atherosclerotic lesions. Up to now, there is no consensus on the contribution of membrane-bound UPA and its receptor CD87 (UPAR) to the development of atherosclerosis. In this study, we determined comparatively the levels of UPAR and UPAR-bound UPA in segments of human coronary and aortic vessels with different degrees of atherosclerotic lesions (macroscopically normal areas, early atherosclerotic lesions, fibrous and calcified plaques). The UPAR content increased progressively with the severity of atherosclerosis. In aortic segments, in which intima and media layers were analyzed separately, the content of UPAR in the intima significantly exceeded the levels measured in the media. Using a detergent-phase separation method with a Triton X-114-containing buffer, we could demonstrate that the levels of membrane (glycosylphosphatidylinositol)-anchored UPAR were significantly higher in the intima of early atherosclerotic lesions as well as in the cap areas of fibrous plaques compared with macroscopically normal areas. However, only 20-25% of the intimal and 30-50% of the medial glycosylphosphatidylinositol-UPAR was occupied by UPA as determined on a molar basis. These data confirm that the overexpression of UPAR in advanced atherosclerotic lesions contributes to lesion development. Whether UPAR's excess over cell surface UPA provides an additional role for this receptor in atherogenesis besides UPA-mediated proteolysis remains to be elucidated.Keywords
This publication has 54 references indexed in Scilit:
- Release of Soluble Urokinase Receptor from Vascular Cells*Thrombosis and Haemostasis, 2001
- Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteriesAtherosclerosis, 1999
- Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explantsCardiovascular Research, 1997
- Inhibitors of Fibrinolysis Are Elevated in Atherosclerotic PlaqueArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Plasminogen Activator Expression in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Plasminogen Activator System in Human Coronary AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion.Journal of Clinical Investigation, 1995
- Quantification of Plasminogen Activators and Their Inhibitors in the Aortic Vessel Wall in Relation to the Presence and Severity of Atherosclerotic DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.Proceedings of the National Academy of Sciences, 1992